HK1244667A1 - 預防二次感染的方法 - Google Patents

預防二次感染的方法

Info

Publication number
HK1244667A1
HK1244667A1 HK18103208.2A HK18103208A HK1244667A1 HK 1244667 A1 HK1244667 A1 HK 1244667A1 HK 18103208 A HK18103208 A HK 18103208A HK 1244667 A1 HK1244667 A1 HK 1244667A1
Authority
HK
Hong Kong
Prior art keywords
methods
secondary infections
preventing secondary
infections
preventing
Prior art date
Application number
HK18103208.2A
Other languages
English (en)
Inventor
Irit Sagi
Dalit Talmi-Frank
Inna Solomonov
Ido Amit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of HK1244667A1 publication Critical patent/HK1244667A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18103208.2A 2015-02-09 2018-03-06 預防二次感染的方法 HK1244667A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113551P 2015-02-09 2015-02-09
PCT/IL2016/050156 WO2016128975A1 (en) 2015-02-09 2016-02-09 Methods of preventing secondary infections

Publications (1)

Publication Number Publication Date
HK1244667A1 true HK1244667A1 (zh) 2018-08-17

Family

ID=56615084

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103208.2A HK1244667A1 (zh) 2015-02-09 2018-03-06 預防二次感染的方法

Country Status (7)

Country Link
US (2) US10610588B2 (zh)
EP (1) EP3256135A4 (zh)
JP (2) JP6783777B2 (zh)
BR (1) BR112017017115A2 (zh)
CA (1) CA2974925C (zh)
HK (1) HK1244667A1 (zh)
WO (1) WO2016128975A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974925C (en) 2015-02-09 2022-03-22 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
USD841023S1 (en) * 2017-08-24 2019-02-19 Domo, Inc. Display screen or portion thereof with a graphical user interface
EP4168029A4 (en) * 2020-06-19 2024-08-14 Univ Texas ANTI-BST2 ANTIBODIES DIRECTED AGAINST LONG BST2 ISOFORM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
WO2004064728A2 (en) 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
US20050107306A1 (en) * 2003-05-16 2005-05-19 Barr Philip J. Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
AU2014312249A1 (en) 2013-08-28 2016-03-24 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
CA2974925C (en) 2015-02-09 2022-03-22 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections

Also Published As

Publication number Publication date
US10610588B2 (en) 2020-04-07
EP3256135A4 (en) 2018-06-27
WO2016128975A1 (en) 2016-08-18
JP2021020936A (ja) 2021-02-18
CA2974925A1 (en) 2016-08-18
CA2974925C (en) 2022-03-22
JP6783777B2 (ja) 2020-11-11
JP2018507847A (ja) 2018-03-22
EP3256135A1 (en) 2017-12-20
BR112017017115A2 (pt) 2018-04-03
JP7109515B2 (ja) 2022-07-29
US11400156B2 (en) 2022-08-02
US20200261577A1 (en) 2020-08-20
US20180028650A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
HK1243326A1 (zh) 溴結構域抑制劑
HK1245247A1 (zh) 溴結構域的抑制劑
GB2558787B (en) Management of moving objects
SG11201706729SA (en) Derivatives of sobetirome
IL257026A (en) Solid state forms of eluxadoline
SG11201609652RA (en) Treatment of polybacterials infections
PL3470151T3 (pl) Formowanie elementów akumulatora
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL265628A (en) Solid state forms of valbenazine
ZA201706282B (en) Solid forms of menaquinols
IL246979A0 (en) Crystalline forms of sofosbuvir
HK1244274A1 (zh) C21h22ci2n4o2的晶型
GB201904142D0 (en) Improved method of FT-IMS
IL253479A0 (en) Crystalline forms of efinconazole
HK1244667A1 (zh) 預防二次感染的方法
GB201609314D0 (en) Methods of forming compounds
EP3338775A4 (en) USES OF BUTYLIDENEPHTHALIDE
GB2550525B (en) Forming of battery components
IL254666A0 (en) Crystalline forms of Aldecalcitol
HUP1500506A2 (en) Salts of palbociclib
PT3160263T (pt) Composições para prevenção de infeções
GB201721386D0 (en) Chrondogy of time-wave
IL249332A0 (en) Crystalline forms of sofosbuvir